![]() Cell>Point Cell>Point is a biotech company that develops and commercializes molecular imaging and targeted therapeutics. | Tagworks Pharmaceuticals Tagworks Pharmaceuticals is a biotech company that develops antibody-based imaging and therapy | ![]() Viewpoint Molecular Targeting Viewpoint Molecular Targeting is a radiopharmaceutical company that develops alpha-particle therapy for cancer. | ![]() Mersana Therapeutics Mersana Therapeutics is a clinical-stage biotechnology company developing antibody-drug conjugate (ADC) platforms. | ![]() Seagen Seagen (formerly known as Seattle Genetics) is a biotechnology company that develops and commercializes targeted therapies to treat cancer. | |
Founding Date | Founding Date 2001 | Founding Date 2011 | Founding Date 2008 | Founding Date 2005 | Founding Date 1998 |
Type | Type Private | Type Private | Type Subsidiary | Type Public | Type Subsidiary |
Tags | |||||
Locations | Locations Centennial, US HQ | Locations Nijmegen, NL HQ | Locations Coralville, US HQ | Locations Cambridge, US HQ | Locations Bothell, US HQ Mississauga, CA Hørsholm, DK Rueil Malmaison, FR München, DE Milano, IT Schiphol, NL see more |
Employees | Employees 3 | Employees 408% increase | Employees 517% decrease | Employees 11033% increase | Employees 3,25622% increase |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) $40.5m (FY, 2024) | Revenue (est.) $2b (FY, 2022) |
Net income | Net income N/A | Net income N/A | Net income N/A | Net income ($69.2m) (FY, 2024) | Net income ($610.3m) (FY, 2022) |
Funding | |||||
Total funding raised | Total funding raised $ 23.7m | Total funding raised N/A | Total funding raised $ 300k | Total funding raised $ 219.5m | Total funding raised $ 164m |
Tagworks Pharmaceuticals is a biotech company that develops antibody-based imaging and therapy
View company
Viewpoint Molecular Targeting is a radiopharmaceutical company that develops alpha-particle therapy for cancer.
View company
Mersana Therapeutics is a clinical-stage biotechnology company developing antibody-drug conjugate (ADC) platforms.
View company
Seagen (formerly known as Seattle Genetics) is a biotechnology company that develops and commercializes targeted therapies to treat cancer.
View company